banner
Categorïau cynnyrch
Cysylltwch â ni

Cyswllt:Cyfeiliorn Zhou (Mr.)

Ffôn: plws 86-551-65523315

Symudol/WhatsApp: plws 86 17705606359

CQ:196299583

Skype:lucytoday@hotmail.com

E-bost:sales@homesunshinepharma.com

Ychwanegu:1002, Huanmao Adeilad, Rhif 105, Mengcheng Ffordd, Hefei Dinas, 230061, Tsieina

APIs and Intermediates
5-(((S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)-N-((S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl)propanamido)methyl)-2-methoxybenzoic Acid CAS 864821-90-9

5-(((S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)-N-((S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl)propanamido)methyl)-2-methoxybenzoic Acid CAS 864821-90-9

CAS NO:864821-90-9
Molecular Formula:C32H35N5O5
Molecular Weight:569.65
EINECS NO:1592732-453-0
MDL NO: N/A

Manylion y cynnyrch

Product Description

Product Name: 5-(((S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)-N-((S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl)propanamido)methyl)-2-methoxybenzoic acid  CAS NO: 864821-90-9

 

 

Synonyms:

Eluxadoline (Viberzi);

Eluxadoline;

5-({(4-Carbamoyl-2,6-dimethyl-L-phenylalanyl)[(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino}methyl)-2-methoxybenzoic acid;

5-({[(2S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)propanoyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino}methyl)-2-methoxybenzoic acid;

Viberzi;

5-[[[(2S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)propanoyl]-[(1S)-1-(5-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid;

Benzoic acid, 5-[[[(2S)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxy-;

 

 

Chemical & Physical Properties

Appearance :white powder

Assay : ≥99.0%

Density:1.3±0.1 g/cm3

Boiling Point:834.2±65.0 °C at 760 mmHg

Flash Point:458.3±34.3 °C

PSA: 164.63000

LogP :4.35

Vapour Pressure:0.0±3.2 mmHg at 25°C

Index of Refraction:1.640

 

 

Eluxadoline (INN, USAN) (brand name Viberzi vye-BER-zee; former developmental code name JNJ-27018966) is an orally-active drug approved for the treatment of diarrhea and abdominal pain in individuals with diarrhea-predominant irritable bowel syndrome (IBS-D). It was approved for use by the United States Food and Drug Administration on May 27, 2015. The drug originated from Janssen Pharmaceutica and was developed by Actavis.

 

 

If you are interested in our products or have any questions, please feel free to contact us!

 

  

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.

 


Tagiau poblogaidd: 5-(((s)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)-n-((s)-1-(4-phenyl-1h-imidazol-2-yl)ethyl)propanamido)methyl)-2-methoxybenzoic acid cas 864821-90-9, manufacturers, suppliers, factory, buy, in stock

Anfon ymchwiliad